Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Rhea-AI Summary

Theralase (OTCQB:TLTFF) received a receipt for a final base shelf prospectus dated June 29, 2026, filed across Canada. The prospectus enables offerings of up to C$100 million in various securities over 25 months, though the company currently has no intention to issue securities.

Positive

• Base shelf prospectus enables up to C$100 million in financing over 25 months
• Flexible mix of securities allowed: common shares, warrants, subscription receipts, and debt
• Financing capacity intended to support key cancer, virus and bacteria R&D platforms
• Potential funding for pivotal non-muscle invasive bladder cancer clinical program and oncology pipeline

Negative

• Future use of the prospectus could lead to shareholder dilution from new securities
• Uncertainty on timing and terms of any future offerings under the shelf

News Market Reaction – TLTFF

+1.14%

+1.14% Session close to close

In the Jul 1 session, TLTFF gained 1.14%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("Prospectus") with the securities regulatory authorities in all provinces and territories of Canada.

The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof (collectively, the "Securities"), over a 25-month period.

Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase®, stated, "The approval of the Prospectus represents an important milestone for the Company, providing up to C$100 Million of capital, if and when required, to fund the commercial development of various cancer, virus and bacteria platforms. Access to capital markets, as opportunities arise, supports our corporate strategy of simultaneously advancing numerous, value-driven strategic initiatives; including, our pivotal non-muscle invasive bladder cancer clinical program, our pipeline of various oncological conditions and the continued development of our pharmaceutical platform. The Company believes that maintaining access to flexible financing will support its ongoing efforts to create long-term shareholder value, through successful achievement of key clinical, regulatory and commercial milestones."

Any future offering under the Prospectus will be made by way of a Prospectus supplement containing specific terms of the offering and will be filed with the applicable securities regulatory authorities. The Company has no present intention to offer the Securities pursuant to the Prospectus.

For a copy of the Prospectus, please refer to the Company's SEDAR+ profile at www.sedarplus.ca.

About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedarplus.ca.

Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; access to sufficient capital to fund the Company's operations is available on terms that are commercially favourable to the Company or at all; the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.

For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303567

FAQ

What did Theralase (OTCQB:TLTFF) announce on June 30, 2026?

Theralase announced it received a receipt for a final base shelf prospectus allowing offerings of up to C$100 million in securities. According to Theralase, this facility is available for 25 months, with no current plan to issue securities.

How much can Theralase raise under its new base shelf prospectus (TLTFF)?

Theralase can offer up to C$100 million of securities under the new base shelf prospectus. According to Theralase, this may include common shares, warrants, subscription receipts, debt, or combinations, to support clinical, regulatory, and commercial initiatives over 25 months.

What types of securities can Theralase (TLTFF) issue under the C$100 million shelf?

Theralase may issue common shares, warrants, subscription receipts, debt securities, or any combination thereof. According to Theralase, these instruments provide flexible financing options to fund cancer, bacteria, and virus platforms and its non-muscle invasive bladder cancer clinical program.

Does Theralase plan an immediate stock offering under the new base shelf (TLTFF)?

Theralase states it has no present intention to offer securities under the new prospectus. According to Theralase, any future offering would require a separate prospectus supplement detailing terms and be filed with securities regulators before proceeding.

How could the C$100 million shelf prospectus impact Theralase shareholders (TLTFF)?

The shelf prospectus gives Theralase potential access to up to C$100 million in capital over 25 months. According to Theralase, this flexibility may fund key programs, though any future issuances could dilute existing shareholders depending on structure and pricing.

How long is Theralase’s C$100 million base shelf prospectus effective?

The base shelf prospectus permits offerings for a period of 25 months from its date. According to Theralase, any specific financing during this window would use a prospectus supplement outlining detailed terms and filed with Canadian securities regulators.